Drug‑resistant feline infectious peritonitis virus (FIP‑V) variants pose major obstacles to single‑agent antiviral intervention, driving treatment failure and clinical relapse in feline infectious peritonitis (FIP) research models. GS‑441524 (nucleoside analog RdRp inhibitor) and GC376 (3CL‑pro protease inhibitor) represent two well‑characterized research‑grade antiviral compounds targeting distinct coronavirus replication mechanisms. This complete research compound catalog summarizes combination‑therapy rationales, in‑vitro potency data, resistance‑breaking mechanisms, compound specifications, assay references and published protocol resources for GS‑441524 plus GC376 against drug‑resistant FIP‑V isolates. Dual‑target suppression elevates the viral genetic barrier to escape mutations compared with monotherapy. Designed for virology laboratories, pre‑clinical drug‑development groups and FIP‑V antiviral screening projects, this catalog consolidates critical compound metadata to accelerate combination‑antiviral research against drug‑resistant feline coronavirus strains.